血脂异常基层合理用药指南

2021-01-02 中华医学会心血管病学分会中华全科医师杂志

血脂异常通常指血浆中总胆固醇(total cholesterol,TC)和/或甘油三酯(triglycerid,TG)升高,因为脂质不溶或微溶于水,必须与蛋白质结合以脂蛋白形式存在才能在血液中循环。

中文标题：

血脂异常基层合理用药指南

发布机构：

中华医学会心血管病学分会

发布日期：

2021-01-02

简要介绍：

血脂异常通常指血浆中总胆固醇(total cholesterol,TC)和/或甘油三酯(triglycerid,TG)升高,因为脂质不溶或微溶于水,必须与蛋白质结合以脂蛋白形式存在才能在血液中循环,所以血脂异常是通过高脂蛋白血症表现出来的,统称为高脂蛋白血症(hyperlipoproteinemia),简称为高脂血症(hyperlipidemia)。实际上高脂血症也泛指包括低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)升高、高密度脂蛋白胆固醇(high-density lipoprotein cholesterol,HDL-C)降低等在内的各种血脂异常。

下载附件：

点击下载

(因为版权问题，不支持下载)

评论区 (18)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1212115, encodeId=f0f0121211547, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5db65480276, createdName=ms1000001687352890, createdTime=Mon Apr 18 10:27:11 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212114, encodeId=f7921212114f2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5db65480276, createdName=ms1000001687352890, createdTime=Mon Apr 18 10:26:41 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212113, encodeId=f94e1212113a1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5db65480276, createdName=ms1000001687352890, createdTime=Mon Apr 18 10:26:13 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203608, encodeId=c232120360848, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24b56553443, createdName=ms5000000573654290, createdTime=Thu Mar 17 21:56:21 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194909, encodeId=a62d1194909dc, content=血脂异常, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcbc6454654, createdName=ms8000001465072660, createdTime=Fri Feb 18 21:54:29 CST 2022, time=2022-02-18, status=1, ipAttribution=)]
2022-04-18 ms1000001687352890

感谢分享

60 0
[GetPortalCommentsPageByObjectIdResponse(id=1212115, encodeId=f0f0121211547, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5db65480276, createdName=ms1000001687352890, createdTime=Mon Apr 18 10:27:11 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212114, encodeId=f7921212114f2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5db65480276, createdName=ms1000001687352890, createdTime=Mon Apr 18 10:26:41 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212113, encodeId=f94e1212113a1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5db65480276, createdName=ms1000001687352890, createdTime=Mon Apr 18 10:26:13 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203608, encodeId=c232120360848, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24b56553443, createdName=ms5000000573654290, createdTime=Thu Mar 17 21:56:21 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194909, encodeId=a62d1194909dc, content=血脂异常, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcbc6454654, createdName=ms8000001465072660, createdTime=Fri Feb 18 21:54:29 CST 2022, time=2022-02-18, status=1, ipAttribution=)]
2022-04-18 ms1000001687352890

学习

48 0
[GetPortalCommentsPageByObjectIdResponse(id=1212115, encodeId=f0f0121211547, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5db65480276, createdName=ms1000001687352890, createdTime=Mon Apr 18 10:27:11 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212114, encodeId=f7921212114f2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5db65480276, createdName=ms1000001687352890, createdTime=Mon Apr 18 10:26:41 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212113, encodeId=f94e1212113a1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5db65480276, createdName=ms1000001687352890, createdTime=Mon Apr 18 10:26:13 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203608, encodeId=c232120360848, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24b56553443, createdName=ms5000000573654290, createdTime=Thu Mar 17 21:56:21 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194909, encodeId=a62d1194909dc, content=血脂异常, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcbc6454654, createdName=ms8000001465072660, createdTime=Fri Feb 18 21:54:29 CST 2022, time=2022-02-18, status=1, ipAttribution=)]
2022-04-18 ms1000001687352890

学习

55 0
[GetPortalCommentsPageByObjectIdResponse(id=1212115, encodeId=f0f0121211547, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5db65480276, createdName=ms1000001687352890, createdTime=Mon Apr 18 10:27:11 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212114, encodeId=f7921212114f2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5db65480276, createdName=ms1000001687352890, createdTime=Mon Apr 18 10:26:41 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212113, encodeId=f94e1212113a1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5db65480276, createdName=ms1000001687352890, createdTime=Mon Apr 18 10:26:13 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203608, encodeId=c232120360848, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24b56553443, createdName=ms5000000573654290, createdTime=Thu Mar 17 21:56:21 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194909, encodeId=a62d1194909dc, content=血脂异常, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcbc6454654, createdName=ms8000001465072660, createdTime=Fri Feb 18 21:54:29 CST 2022, time=2022-02-18, status=1, ipAttribution=)]
2022-03-17 ms5000000573654290

感谢分享

54 0
[GetPortalCommentsPageByObjectIdResponse(id=1212115, encodeId=f0f0121211547, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5db65480276, createdName=ms1000001687352890, createdTime=Mon Apr 18 10:27:11 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212114, encodeId=f7921212114f2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5db65480276, createdName=ms1000001687352890, createdTime=Mon Apr 18 10:26:41 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212113, encodeId=f94e1212113a1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5db65480276, createdName=ms1000001687352890, createdTime=Mon Apr 18 10:26:13 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203608, encodeId=c232120360848, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24b56553443, createdName=ms5000000573654290, createdTime=Thu Mar 17 21:56:21 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194909, encodeId=a62d1194909dc, content=血脂异常, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcbc6454654, createdName=ms8000001465072660, createdTime=Fri Feb 18 21:54:29 CST 2022, time=2022-02-18, status=1, ipAttribution=)]
2022-02-18 ms8000001465072660

血脂异常

59 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

心血管指南

血脂异常基层合理用药指南

相关指南

拓展阅读

科室

工具

服务